SAR 55.9
(2.57%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 12.26 Million SAR | 15.01% |
2022 | 10.66 Million SAR | 24.5% |
2021 | 8.56 Million SAR | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 3.97 Million SAR | 0.0% |
2024 Q1 | 3.97 Million SAR | 2.87% |
2023 Q3 | 3.86 Million SAR | -5.21% |
2023 Q4 | 3.86 Million SAR | 0.0% |
2023 FY | 12.26 Million SAR | 15.01% |
2023 Q2 | 4.08 Million SAR | 0.0% |
2023 Q1 | 4.08 Million SAR | 15.67% |
2022 FY | 10.66 Million SAR | 24.5% |
2022 Q4 | 3.52 Million SAR | 0.0% |
2021 FY | 8.56 Million SAR | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Middle East Pharmaceutical Industries Co. | 128.79 Million SAR | 90.48% |
Al-Dawaa Medical Services Company | 1.59 Billion SAR | 99.233% |
Nahdi Medical Company | 2.47 Billion SAR | 99.505% |
Almujtama Alraida Medical Co. | 115.25 Million SAR | 89.362% |